Clinicopathologic Features of TDO2 Overexpression in Renal Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Jun 27

PMID 34174844

Citations 5

Authors

Quoc Thang Pham

Daiki Taniyama

Yohei Sekino

Shintaro Akabane

Takashi Babasaki

Go Kobayashi

Naoya Sakamoto

Kazuhiro Sentani

Naohide Oue

Wataru Yasui

Affiliations

Soon will be listed here.

Abstract

Background: Tryptophan 2,3-dioxygenase (TDO2) is the primary enzyme catabolizing tryptophan. Several lines of evidence revealed that overexpression of TDO2 is involved in anoikis resistance, spheroid formation, proliferation, and invasion and correlates with poor prognosis in some cancers. The aim of this research was to uncover the expression and biofunction of TDO2 in renal cell carcinoma (RCC).

Methods: To show the expression of TDO2 in RCC, we performed qRT-PCR and immunohistochemistry in integration with TCGA data analysis. The interaction of TDO2 with PD-L1, CD44, PTEN, and TDO2 expression was evaluated. We explored proliferation, colony formation, and invasion in RCC cells line affected by knockdown of TDO2.

Results: RNA-Seq and immunohistochemical analysis showed that TDO2 expression was upregulated in RCC tissues and was associated with advanced disease and poor survival of RCC patients. Furthermore, TDO2 was co-expressed with PD-L1 and CD44. In silico analysis and in vitro knockout of PTEN in RCC cell lines revealed the ability of PTEN to regulate the expression of TDO2. Knockdown of TDO2 suppressed the proliferation and invasion of RCC cells.

Conclusion: Our results suggest that TDO2 might have an important role in disease progression and could be a promising marker for targeted therapy in RCC. (199 words).

Citing Articles

TDO2 + cancer-associated fibroblasts mediate cutaneous squamous cell carcinoma immune escape via impeding infiltration of CD8 + T cells.

Lu F, Yan G, Zhao Z, Zheng Z, Wu Y, Wen L Cancer Immunol Immunother. 2025; 74(2):67.

PMID: 39751882 PMC: 11698999. DOI: 10.1007/s00262-024-03921-0.

Whole transcriptome expression profiles in kidney samples from rats with hyperuricaemic nephropathy.

Li N, Amatjan M, He P, Wu M, Yan H, Shao X PLoS One. 2022; 17(12):e0276591.

PMID: 36534664 PMC: 9762607. DOI: 10.1371/journal.pone.0276591.

A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma.

Chen Z, Liu X, Zhu Z, Chen J, Wang C, Chen X Front Genet. 2022; 13:1039465.

PMID: 36338978 PMC: 9627172. DOI: 10.3389/fgene.2022.1039465.

Pancancer Analysis of Revealed as a Biomarker of Prognosis and Immunotherapy.

Cui J, Tian Y, Liu T, Lin X, Li L, Li Z Dis Markers. 2022; 2022:5447017.

PMID: 36118672 PMC: 9481368. DOI: 10.1155/2022/5447017.

Dexamethasone Promotes a Stem-Like Phenotype in Human Melanoma Cells Tryptophan 2,3 Dioxygenase.

Cecchi M, Mannini A, Lapucci A, Silvano A, Lulli M, Luceri C Front Pharmacol. 2022; 13:911019.

PMID: 35847038 PMC: 9280025. DOI: 10.3389/fphar.2022.911019.

References

Linehan W, Spellman P, Ricketts C, Creighton C, Fei S, Davis C . Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2015; 374(2):135-45. PMC: 4775252. DOI: 10.1056/NEJMoa1505917. View

Takeuchi K, Ito F . EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2009; 277(2):316-26. DOI: 10.1111/j.1742-4658.2009.07450.x. View

Davis C, Ricketts C, Wang M, Yang L, Cherniack A, Shen H . The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014; 26(3):319-330. PMC: 4160352. DOI: 10.1016/j.ccr.2014.07.014. View

Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S . Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016; 34(8):1081-6. DOI: 10.1007/s00345-016-1773-y. View

Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E . The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018; 23(1):313-326.e5. PMC: 6075733. DOI: 10.1016/j.celrep.2018.03.075. View

Platten M, Wick W, Van den Eynde B . Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012; 72(21):5435-40. DOI: 10.1158/0008-5472.CAN-12-0569. View

Buitenhuis M, Verhagen L, van Deutekom H, Castor A, Verploegen S, Koenderman L . Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood. 2007; 111(1):112-21. DOI: 10.1182/blood-2006-07-037572. View

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R . Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A. 2012; 109(7):2497-502. PMC: 3289319. DOI: 10.1073/pnas.1113873109. View

Badawy A . Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res. 2017; 10:1178646917691938. PMC: 5398323. DOI: 10.1177/1178646917691938. View

10.

Choueiri T, Motzer R . Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017; 376(4):354-366. DOI: 10.1056/NEJMra1601333. View

11.

Pham Q, Oue N, Yamamoto Y, Shigematsu Y, Sekino Y, Sakamoto N . The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell Carcinoma. Anticancer Res. 2017; 37(6):2853-2860. DOI: 10.21873/anticanres.11637. View

12.

Crotti S, Fraccaro A, Bedin C, Bertazzo A, Di Marco V, Pucciarelli S . Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients. Front Oncol. 2020; 10:583228. PMC: 7593679. DOI: 10.3389/fonc.2020.583228. View

13.

Yasui W, Ayhan A, Kitadai Y, Nishimura K, Yokozaki H, Ito H . Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer. 1993; 53(1):36-41. DOI: 10.1002/ijc.2910530108. View

14.

Pandey N, Lanke V, Vinod P . Network-based metabolic characterization of renal cell carcinoma. Sci Rep. 2020; 10(1):5955. PMC: 7136214. DOI: 10.1038/s41598-020-62853-8. View

15.

DAmato N, Rogers T, Gordon M, Greene L, Cochrane D, Spoelstra N . A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015; 75(21):4651-64. PMC: 4631670. DOI: 10.1158/0008-5472.CAN-15-2011. View

16.

Kudo T, Prentzell M, Mohapatra S, Sahm F, Zhao Z, Grummt I . Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ. Front Immunol. 2020; 11:657. PMC: 7239998. DOI: 10.3389/fimmu.2020.00657. View

17.

Ye M, Zhang Y, Gao H, Xu Y, Jing P, Wu J . Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. Clin Cancer Res. 2017; 24(5):1227-1239. DOI: 10.1158/1078-0432.CCR-17-0396. View

18.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

19.

Opitz C, Litzenburger U, Sahm F, Ott M, Tritschler I, Trump S . An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478(7368):197-203. DOI: 10.1038/nature10491. View

20.

Thomas R, Weihua Z . Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol. 2019; 9:800. PMC: 6716122. DOI: 10.3389/fonc.2019.00800. View